MX2020008559A - Compuestos heterocíclicos como inhibidores de la quinasa. - Google Patents

Compuestos heterocíclicos como inhibidores de la quinasa.

Info

Publication number
MX2020008559A
MX2020008559A MX2020008559A MX2020008559A MX2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
kinase inhibitors
compounds
find
cdk6
Prior art date
Application number
MX2020008559A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Jiyun Chen
Anil Kumar Agarwal
Brahmam Pujala
Bhawana Bhatt
Jayakanth Kankanala
Amit Shete
Sanjeev Soni
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of MX2020008559A publication Critical patent/MX2020008559A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos heterocíclicos como inhibidores de CDK4 o CDK6 u otros inhibidores de CDK; los compuestos pueden usarse como agentes terapéuticos para el tratamiento de enfermedades y pueden usarse particularmente en oncología.
MX2020008559A 2018-02-15 2019-02-15 Compuestos heterocíclicos como inhibidores de la quinasa. MX2020008559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862631437P 2018-02-15 2018-02-15
PCT/US2019/018244 WO2019161224A1 (en) 2018-02-15 2019-02-15 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2020008559A true MX2020008559A (es) 2021-01-08

Family

ID=67542098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008559A MX2020008559A (es) 2018-02-15 2019-02-15 Compuestos heterocíclicos como inhibidores de la quinasa.

Country Status (13)

Country Link
US (2) US11174252B2 (es)
EP (1) EP3752491A4 (es)
JP (1) JP2021514359A (es)
KR (1) KR20200131246A (es)
CN (1) CN112334451A (es)
AU (1) AU2019220746A1 (es)
BR (1) BR112020015431A2 (es)
CA (1) CA3089592A1 (es)
IL (1) IL276509A (es)
MA (1) MA51846A (es)
MX (1) MX2020008559A (es)
SG (1) SG11202007754UA (es)
WO (1) WO2019161224A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728228A1 (en) * 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
KR102797697B1 (ko) 2018-05-25 2025-04-22 에이2에이 파마수티칼스, 잉크. 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP4013753A1 (en) * 2019-08-14 2022-06-22 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
BR112022002532A2 (pt) * 2019-08-14 2022-07-19 Nuvation Bio Inc Compostos heterocíclicos como inibidores de quinase
CN113244386A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
JP7807381B2 (ja) * 2020-03-02 2026-01-27 シロナックス リミテッド． フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
WO2022078309A1 (zh) * 2020-10-12 2022-04-21 上海海雁医药科技有限公司 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
US20220259195A1 (en) * 2021-02-03 2022-08-18 Nuvation Bio Inc. Crystalline forms of a cyclin-dependent kinase inhibitor
WO2022221194A1 (en) * 2021-04-12 2022-10-20 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
WO2022236257A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236256A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236255A2 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236253A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN113264920B (zh) * 2021-05-10 2022-09-02 中国药科大学 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用
WO2022261643A1 (en) * 2021-06-09 2022-12-15 Nuvation Bio Inc. Treating cancers with a cyclin-dependent kinase inhibitor
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS
US20240050577A1 (en) * 2022-04-27 2024-02-15 Risen (Suzhou) Pharma Tech Co., Ltd. Cdk inhibitors and pharmaceutical uses thereof
CA3250944A1 (en) * 2022-04-29 2023-11-02 Beigene , Ltd. 7-(PYRIMIDIN-4-YL)QUINOLIN-4 (1H)-ONE SUBSTITUTED COMPOUNDS AS CYCLINE-DEPENDENT KINASE INHIBITORS
IL318171A (en) * 2022-07-29 2025-03-01 Allorion Therapeutics Inc Aminoheteroaryl kinase inhibitors
KR20250054814A (ko) * 2022-09-05 2025-04-23 티와이케이 메디슨즈, 인코포레이티드 Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도
WO2024107746A1 (en) * 2022-11-15 2024-05-23 Larkspur Biosciences Inhibitors and degraders of pip4k protein
WO2025007859A1 (en) * 2023-07-03 2025-01-09 Insilico Medicine Ip Limited Substituted thiazole compounds as cdk2/4/6 inhibitors and methods of use thereof
WO2025247364A1 (zh) * 2024-05-30 2025-12-04 山东先声生物制药有限公司 杂环化合物作为cdk抑制剂及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200506A (et) 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
ES2292753T4 (es) * 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
US7259161B2 (en) * 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
BRPI0513899A (pt) 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de cinase heterocìclica de anel fundido
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
ES2348997T3 (es) 2005-08-25 2010-12-21 Schering Corporation Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c.
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
EA019094B1 (ru) 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2580213A4 (en) 2010-06-09 2013-12-25 Afraxis Holdings Inc 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
US20130252967A1 (en) 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156775A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
ES2525866T3 (es) 2010-08-05 2014-12-30 Temple University - Of The Commonwealth System Of Higher Education 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2013175415A1 (en) 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CA2906166C (en) 2013-03-15 2023-03-14 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US10016439B2 (en) 2014-01-31 2018-07-10 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
RU2671494C2 (ru) 2014-05-28 2018-11-01 Шанхай Фокон Фармасьютикал Ко., Лтд Некоторые ингибиторы протеинкиназы
WO2016015604A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
ES2806206T3 (es) 2015-03-11 2021-02-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado de 2-hidrógeno pirazol sustituido que sirve como fármaco anticanceroso
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
US11225492B2 (en) 2015-12-13 2022-01-18 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN108779117B (zh) 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
TWI736578B (zh) 2016-02-06 2021-08-21 大陸商上海複尚慧創醫藥研究有限公司 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
CN107286134B (zh) 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
IL307931A (en) 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
RU2738837C2 (ru) 2016-05-07 2020-12-17 Шанхай Фокон Фармасьютикал Ко., Лтд. Некоторые ингибиторы протеинкиназы
KR102445288B1 (ko) 2016-07-01 2022-09-19 쥐원 쎄라퓨틱스, 인크. N-(헤테로아릴)-피롤로[3,2-d]피리미딘-2-아민의 합성
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
CA3039012C (en) 2016-11-11 2021-08-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
TWI732083B (zh) 2016-12-22 2021-07-01 大陸商貝達藥業股份有限公司 苯并咪唑衍生物、其藥物組合物及其應用
CN107382974B (zh) 2017-06-08 2020-06-05 扬州市三药制药有限公司 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用
CA3088381A1 (en) 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
US12312346B2 (en) 2018-06-27 2025-05-27 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
WO2020023480A1 (en) 2018-07-23 2020-01-30 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CN112703186A (zh) 2018-07-27 2021-04-23 加利福尼亚技术学院 Cdk抑制剂及其用途
CN110835334B (zh) 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020108661A1 (zh) 2018-11-30 2020-06-04 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用

Also Published As

Publication number Publication date
BR112020015431A2 (pt) 2020-12-08
JP2021514359A (ja) 2021-06-10
US20190248774A1 (en) 2019-08-15
SG11202007754UA (en) 2020-09-29
EP3752491A1 (en) 2020-12-23
US11174252B2 (en) 2021-11-16
US20230062022A1 (en) 2023-03-02
IL276509A (en) 2020-09-30
AU2019220746A1 (en) 2020-08-27
CA3089592A1 (en) 2019-08-22
CN112334451A (zh) 2021-02-05
MA51846A (fr) 2021-04-21
KR20200131246A (ko) 2020-11-23
WO2019161224A1 (en) 2019-08-22
EP3752491A4 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
IL275948A (en) History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
JOP20190076A1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
MX2021012418A (es) Compuestos heterociclicos y sus usos.
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
EA200970738A1 (ru) Ингибиторы активности akt
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
ZA201800787B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
SI4419526T1 (sl) Heterociklične spojine za uporabo pri zdravljenju raka
MX2024013266A (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
NZ779815A (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
BR112019007591A2 (pt) inibidores de bromodomínios
WO2022236255A3 (en) Heterocyclic compounds as kinase inhibitors
WO2020106751A8 (en) Inhibitors of gli1 as therapeutic agents
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
JOP20230213A1 (ar) مثبطات حلقية غير متجانسة لكيناز البروتين المتفاعل مع المستقبل-1